FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216484860> ?p ?o ?g. }

• W3216484860 abstract "Abstract Tay-Sachs Disease (TSD) is an inherited neurological disorder caused by deficiency of hexosaminidase A (HexA). Preclinical work demonstrated safety and efficacy of CNS gene therapy using AAVrh8-HEXA/HEXB. Here we describe an expanded access trial in two patients with infantile TSD (IND 18225). Case TSD-001 demonstrated neurodevelopmental regression by 8 months of age and severe seizures by 1 year was treated at 30 months. An equimolar mix of AAVrh8-HEXA and AAVrh8-HEXB (now AXO-AAV-GM2) was administered intrathecally (IT), with 75% of the dose (1x1014vg) delivered to the cisterna magna and 25% at the thoraco-lumbar junction. The second patient (TSD-002) was treated at 7 months of age with 4.2x1013 vg by a combination of bilateral thalamic (0.18 mL; 1.5x1012vg per thalamus), and IT infusion (3.9x1013vg). Both patients underwent immunosuppression with sirolimus, corticosteroids, and rituximab. Injection procedures were well tolerated and have shown no vector-related adverse events to date. CSF HexA activity nearly doubled from baseline and remained stable. In TSD-002 (now 16 months of age), MRI showed stabilization of disease by 3 months post-injection and appeared to temporarily deviate from the natural history of infantile TSD but declined again 6 months post-treatment. TSD-001 (now 4.5 years of age remains seizure-free on the same anti-convulsant therapy as pre-therapy, but TSD-002 developed seizures between 13 and 17 months posttreatment (by 2 years of age). Administration of AXO-AAV-GM2 by IT and thalamic injections was safe, HexA activity increased in CSF and ongoing myelination was apparent in the younger patient treated at an early symptomatic stage. This study provides early safety and proof-of-concept in humans for treatment of TSD patients by AAV gene therapy." @default.
• W3216484860 created "2021-12-06" @default.
• W3216484860 creator A5002238225 @default.
• W3216484860 creator A5005530966 @default.
• W3216484860 creator A5010005871 @default.
• W3216484860 creator A5012979601 @default.
• W3216484860 creator A5016421958 @default.
• W3216484860 creator A5017526559 @default.
• W3216484860 creator A5017592912 @default.
• W3216484860 creator A5019086970 @default.
• W3216484860 creator A5019389583 @default.
• W3216484860 creator A5025571618 @default.
• W3216484860 creator A5027955149 @default.
• W3216484860 creator A5028073719 @default.
• W3216484860 creator A5036919823 @default.
• W3216484860 creator A5037604059 @default.
• W3216484860 creator A5040082469 @default.
• W3216484860 creator A5041224499 @default.
• W3216484860 creator A5043437811 @default.
• W3216484860 creator A5050412390 @default.
• W3216484860 creator A5057653702 @default.
• W3216484860 creator A5058091002 @default.
• W3216484860 creator A5060374817 @default.
• W3216484860 creator A5065878193 @default.
• W3216484860 creator A5068733896 @default.
• W3216484860 creator A5077905008 @default.
• W3216484860 creator A5083359786 @default.
• W3216484860 creator A5085859061 @default.
• W3216484860 creator A5089625422 @default.
• W3216484860 creator A5091851465 @default.
• W3216484860 date "2021-02-18" @default.
• W3216484860 modified "2023-10-03" @default.
• W3216484860 title "First-in-human AAV Gene Therapy for Tay-Sachs Disease" @default.
• W3216484860 doi "https://doi.org/10.21203/rs.3.rs-195847/v1" @default.
• W3216484860 hasPublicationYear "2021" @default.
• W3216484860 type Work @default.
• W3216484860 sameAs 3216484860 @default.
• W3216484860 citedByCount "2" @default.
• W3216484860 countsByYear W32164848602022 @default.
• W3216484860 crossrefType "posted-content" @default.
• W3216484860 hasAuthorship W3216484860A5002238225 @default.
• W3216484860 hasAuthorship W3216484860A5005530966 @default.
• W3216484860 hasAuthorship W3216484860A5010005871 @default.
• W3216484860 hasAuthorship W3216484860A5012979601 @default.
• W3216484860 hasAuthorship W3216484860A5016421958 @default.
• W3216484860 hasAuthorship W3216484860A5017526559 @default.
• W3216484860 hasAuthorship W3216484860A5017592912 @default.
• W3216484860 hasAuthorship W3216484860A5019086970 @default.
• W3216484860 hasAuthorship W3216484860A5019389583 @default.
• W3216484860 hasAuthorship W3216484860A5025571618 @default.
• W3216484860 hasAuthorship W3216484860A5027955149 @default.
• W3216484860 hasAuthorship W3216484860A5028073719 @default.
• W3216484860 hasAuthorship W3216484860A5036919823 @default.
• W3216484860 hasAuthorship W3216484860A5037604059 @default.
• W3216484860 hasAuthorship W3216484860A5040082469 @default.
• W3216484860 hasAuthorship W3216484860A5041224499 @default.
• W3216484860 hasAuthorship W3216484860A5043437811 @default.
• W3216484860 hasAuthorship W3216484860A5050412390 @default.
• W3216484860 hasAuthorship W3216484860A5057653702 @default.
• W3216484860 hasAuthorship W3216484860A5058091002 @default.
• W3216484860 hasAuthorship W3216484860A5060374817 @default.
• W3216484860 hasAuthorship W3216484860A5065878193 @default.
• W3216484860 hasAuthorship W3216484860A5068733896 @default.
• W3216484860 hasAuthorship W3216484860A5077905008 @default.
• W3216484860 hasAuthorship W3216484860A5083359786 @default.
• W3216484860 hasAuthorship W3216484860A5085859061 @default.
• W3216484860 hasAuthorship W3216484860A5089625422 @default.
• W3216484860 hasAuthorship W3216484860A5091851465 @default.
• W3216484860 hasBestOaLocation W32164848601 @default.
• W3216484860 hasConcept C104317684 @default.
• W3216484860 hasConcept C111599444 @default.
• W3216484860 hasConcept C126322002 @default.
• W3216484860 hasConcept C141071460 @default.
• W3216484860 hasConcept C155647269 @default.
• W3216484860 hasConcept C185592680 @default.
• W3216484860 hasConcept C187212893 @default.
• W3216484860 hasConcept C197934379 @default.
• W3216484860 hasConcept C2778098279 @default.
• W3216484860 hasConcept C2779134260 @default.
• W3216484860 hasConcept C2779390119 @default.
• W3216484860 hasConcept C55493867 @default.
• W3216484860 hasConcept C71924100 @default.
• W3216484860 hasConcept C97343561 @default.
• W3216484860 hasConceptScore W3216484860C104317684 @default.
• W3216484860 hasConceptScore W3216484860C111599444 @default.
• W3216484860 hasConceptScore W3216484860C126322002 @default.
• W3216484860 hasConceptScore W3216484860C141071460 @default.
• W3216484860 hasConceptScore W3216484860C155647269 @default.
• W3216484860 hasConceptScore W3216484860C185592680 @default.
• W3216484860 hasConceptScore W3216484860C187212893 @default.
• W3216484860 hasConceptScore W3216484860C197934379 @default.
• W3216484860 hasConceptScore W3216484860C2778098279 @default.
• W3216484860 hasConceptScore W3216484860C2779134260 @default.
• W3216484860 hasConceptScore W3216484860C2779390119 @default.
• W3216484860 hasConceptScore W3216484860C55493867 @default.
• W3216484860 hasConceptScore W3216484860C71924100 @default.
• W3216484860 hasConceptScore W3216484860C97343561 @default.
• W3216484860 hasLocation W32164848601 @default.
• W3216484860 hasOpenAccess W3216484860 @default.
• W3216484860 hasPrimaryLocation W32164848601 @default.

• next